Multiple Sclerosis News and Research RSS Feed - Multiple Sclerosis News and Research

Multiple sclerosis (MS) is a severe autoimmune disease of the central nervous system that affects the brain and spinal cord, causing problems with muscle movement, balance and vision.

In MS, the protein coating called myelin, which protects nerves and helps electrical signals travel from the brain to the rest of the body, is damaged. The immune system, which usually fights infection, mistakes myelin for a foreign body and attacks it, stripping it from around the nerves. Exactly what causes this abnormal immune response is unclear, but research suggests a combination of both genetic and environmental factors.

The damaged myelin disrupts the transfer of nerve signals which may slow down, become distorted or stop altogether. This can cause severe symptoms ranging from vision loss through to muscle stiffness, loss of control over muscle movement, difficulties with balance and poor co-ordination.

Around 100,000 people in the UK have MS and it affects about three times as many women as men. The usual age at which diagnosis occurs is around 30, however, symptoms often first develop between the ages of 15 and 45.

Currently, there is no cure for MS but therapeutic approaches such as physiotherapy and steroid injections are used to manage the condition and ease symptoms.
Researchers shed light on involvement of immune system in schizophrenia

Researchers shed light on involvement of immune system in schizophrenia

Using data from the largest ever genetic study of schizophrenia, researchers have shed light on the role of the immune system. [More]
Researchers develop antibody with potential therapeutic effects against multiple sclerosis

Researchers develop antibody with potential therapeutic effects against multiple sclerosis

Inserm Unit U919, directed by Prof. Denis Vivien has developed an antibody with potential therapeutic effects against multiple sclerosis. [More]
Postmenopausal estrogen supplement may not affect memory of healthy women

Postmenopausal estrogen supplement may not affect memory of healthy women

Contrary to popular belief, taking estrogen after menopause may not affect the memory and thinking abilities of healthy women no matter when the treatment is started. [More]
VIB research reveals new insights into ALS

VIB research reveals new insights into ALS

Research into amyotrophic lateral sclerosis (ALS) conducted by VIB-KU Leuven has led to interesting and unexpected conclusions. [More]
Genes linked to Alzheimer's disease may show effects on the brain from childhood

Genes linked to Alzheimer's disease may show effects on the brain from childhood

A gene associated with Alzheimer's disease and recovery after brain injury may show its effects on the brain and thinking skills as early as childhood, according to a study published in the July 13, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Fecal transplants may help treat home and hospital-acquired scourge

Fecal transplants may help treat home and hospital-acquired scourge

Fecal transplants are increasingly being used as the treatment of last resort for certain infections in the human gut and have had remarkable success treating the nursing home and hospital-acquired scourge, Clostridium difficile colitis, an infectious diarrhea that often follows antibiotic treatment. [More]
MS patients have different patterns of gut microorganisms than healthy counterparts

MS patients have different patterns of gut microorganisms than healthy counterparts

A connection between the bacteria living in the gut and immunological disorders such as multiple sclerosis have long been suspected, but for the first time, researchers have detected clear evidence of changes that tie the two together. [More]
Diversity of gut bacteria may affect brain health

Diversity of gut bacteria may affect brain health

The surprising and potentially wide-ranging effects that the levels and diversity of bacteria living in the gut have on overall human health, inflammation, and specifically brain health are the focus of a provocative interview with Dr. David Perlmutter in Alternative and Complementary Therapies, a journal from Mary Ann Liebert, Inc., publishers. [More]
New study identifies four subtypes of human insulin producing beta cells involved in diabetes

New study identifies four subtypes of human insulin producing beta cells involved in diabetes

A new study led by nationally prominent stem cell scientist Markus Grompe, M.D., has determined the existence of at least four separate subtypes of human insulin producing beta cells that may be important in the understanding and treatment of diabetes. The findings were published online today in the journal Nature Communications. [More]
AAN, ABF and MDA offer new two-year clinical training fellowship in muscular dystrophy

AAN, ABF and MDA offer new two-year clinical training fellowship in muscular dystrophy

The American Academy of Neurology, the American Brain Foundation and the Muscular Dystrophy Association have announced a new Clinical Research Training Fellowship in muscular dystrophy for 2017. [More]
AAN announces winners of 2016 Neuro Film Festival

AAN announces winners of 2016 Neuro Film Festival

The American Academy of Neurology is pleased to announce the winning entries to the 2016 Neuro Film Festival. [More]
Athletes may experience long-term brain changes after sports-related concussion

Athletes may experience long-term brain changes after sports-related concussion

New research finds white matter changes in the brains of athletes six months after a concussion. The study will be presented at the Sports Concussion Conference in Chicago, July 8-10, hosted by the American Academy of Neurology, the world's leading authority on the diagnosis and management of sports-related concussion. [More]
New research shows how cholesterol medicine has beneficial effect on immune defence system

New research shows how cholesterol medicine has beneficial effect on immune defence system

The cholesterol medicine simvastatin, which is one of the most commonly used pharmaceuticals in the world, also has a beneficial effect on the immune defence system with regard to diseases such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis. [More]
Hippocampal inflammation linked to depressive symptoms in patients with multiple sclerosis

Hippocampal inflammation linked to depressive symptoms in patients with multiple sclerosis

Patients with multiple sclerosis have higher rates of depression than the general population, including people with other life-long disabling diseases. Symptoms of multiple sclerosis arise from an abnormal response of the body's immune system. [More]
Genetic risk score may help detect Alzheimer's disease risk in healthy young adults

Genetic risk score may help detect Alzheimer's disease risk in healthy young adults

New research shows that a genetic risk score may detect those at higher risk for Alzheimer's disease long before symptoms appear—even possibly in healthy young adults, according to a study published in the July 6, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Review examines role of gut microbes in development, progression of MS

Review examines role of gut microbes in development, progression of MS

An increasing number of clinical studies are pointing to a link between the autoimmune disease multiple sclerosis (MS) and the composition of microbes in the human gut, sparking new research on the gut microbiome as a potential target for MS treatment and prevention. [More]
RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo JUSTE in Spain and additional potential territories

RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, together with IntelGenx Corp., a Canadian drug delivery company focused on oral drug delivery, today announced the signing of an exclusive license agreement with Grupo JUSTE S.A.Q.F (“Grupo JUSTE”), for the commercialization of RIZAPORT™ in Spain, and a right of first refusal for additional territories. RIZAPORT™ is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. [More]
New research highlights need to abandon modern hygiene hypothesis

New research highlights need to abandon modern hygiene hypothesis

The July issue of Perspectives in Public Health (published by the Royal Society of Public Health) takes an objective view of ongoing research showing that the hygiene hypothesis – the idea that allergies are the price we are paying for our “modern obsession with cleanliness” – is a misleading misnomer. [More]
Rapid number naming test can detect cognitively impaired people with AD

Rapid number naming test can detect cognitively impaired people with AD

For the first time, researchers have determined that a brief, simple number naming test can differentiate between cognitively healthy elderly individuals and cognitively impaired people with Alzheimer's disease (AD), including those with mild cognitive impairment (MCI), as well as those with AD dementia. [More]
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
Advertisement
Advertisement